DESTINY-Breast09 Head-to-Head First-Line Phase 3 Trial of ENHERTU® Initiated in Patients with HER2 Positive Metastatic Breast Cancer
Retrieved on:
Monday, June 14, 2021
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Clinical medicine, Cancer, Medicine, Cancer treatments, Breast cancer, Antineoplastic drugs, HER2/neu, Trastuzumab emtansine, Pertuzumab, DESTINY-Breast09, HER2 Positive Breast Cancer, ENHERTU, the ENHERTU Clinical Development Program, Daiichi Sankyo in Oncology, DESTINY-BREAST09, HER2 POSITIVE BREAST CANCER, ENHERTU, THE ENHERTU CLINICAL DEVELOPMENT PROGRAM, DAIICHI SANKYO IN ONCOLOGY
This is the first trial to evaluate ENHERTU in the first-line metastatic setting in patients with HER2 positive breast cancer.
Key Points:
- This is the first trial to evaluate ENHERTU in the first-line metastatic setting in patients with HER2 positive breast cancer.
- In clinical studies, of the 234 patients with unresectable or metastatic HER2-positive breast cancer treated with ENHERTU 5.4 mg/kg, ILD occurred in 9% of patients.
- In clinical studies, of the 234 patients with unresectable or metastatic HER2-positive breast cancer who received ENHERTU 5.4mg/kg, a decrease in neutrophil count was reported in 62% of patients.
- In the 234 patients with unresectable or metastatic HER2-positive breast cancer who received ENHERTU, two cases (0.9%) of asymptomatic LVEF decrease were reported.